MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference:

• 34th Annual Oppenheimer Healthcare Life Sciences Conference
  • Format: Presentation
  • Date and Time: Tuesday, February 13, 2024 at 10:00 am EST
  • Webcast Link: 34th Annual Oppenheimer Healthcare Life Sciences Conference

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine, and acetylcholine systems.

MindMed trades on NASDAQ under the symbol MNMD and on the Cboe Canada exchange (formerly the NEO Exchange) under the symbol MMED.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240207998518/en/

The Mind Medicine (MindMed) Stock at the time of publication of the news with a fall of -0,63 % to 3,788USD on Tradegate stock exchange (07. Februar 2024, 12:18 Uhr).